Skip Navigation

Annals of Oncology 2004 15(9):1373-1376; doi:10.1093/annonc/mdh352
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rogozinska-Szczepka, J.
Right arrow Articles by Wojciechowska-Lacka, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rogozinska-Szczepka, J.
Right arrow Articles by Wojciechowska-Lacka, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society for Medical Oncology

Original Article

BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients

J. Rogozinska-Szczepka1,*, B. Utracka-Hutka1, E. Grzybowska1, B. Maka1, E. Nowicka1, A. Smok-Ragankiewicz1, H. Zientek1, J. Steffen2 and A. Wojciechowska-Lacka3

1 MSC Cancer Centre, Gliwice; 2 MSC Cancer Centre, Warsaw; 3 Wielkopolska Cancer Centre, Poznan, Poland

* Correspondence to: Dr J. Rogozinska-Szczepka, MSC Cancer Centre, Gliwice, Poland. Tel: +48-32-2788717; Fax: +48-32-2788716; Email: utracka{at}io.gliwice.pl

Background: Incidence of primary bilateral breast cancer (BC) is rare and does not exceed 5%. BRCA1/2 mutation carriers diagnosed with breast cancer have a strong life time risk of developing contralateral breast cancer (53% versus 2%).

Patients and methods: A group of 108 patients with bilateral breast cancer, who reported at our Cancer Centres from 2000 to 2002, were subjected to genetic testing. Similarities and differences between BRCA1/2 carriers and non-carriers were analysed in terms of family history, pathology of tumour, age of diagnosis, developing contralateral BC and second primary cancer.

Results: BRCA1/2 mutations were detected in 32 of 108 patients. Family history of BC was identified in 46.9% of these patients compared with 22.4% of non-carriers (P <0.05). Synchronous BC was diagnosed significantly rarer [4 of 32 (12.5%)] in BRCA1/2 carriers than in the non-carrier group [26 of 76 (34.2%)]. In addition, patients with BRCA mutations were younger when they were diagnosed than non-carriers. BRCA1/2 carriers had a significantly higher incidence of medullary BC (13.6% versus 1.7%) and developed ovarian cancer significantly more frequently than non-carriers (12 of 32 and 1 of 72 patients, respectively).

Conclusions: Patients with bilateral BC having BRCA mutations are significantly younger than non-carriers. They also have a significantly higher family history of BC and an increased risk of developing ovarian cancer. The differences in clinical aspects of BRCA carriers with bilateral BC should be considered in clinical management.

Key words: bilateral breast cancer, BRCA1/2, prognostic factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.